If severe perimenopausal hot flushes and night sweats disrupt your daily life, seek clinical evaluation for hormone replacement therapy; do not endure in silence, self-medicate, or use it to prevent heart disease

Menopausal hormone therapy reduces the frequency of moderate-to-severe hot flushes by roughly 75% compared to placebo. However, it carries a small excess risk of breast cancer, deep vein thrombosis, and stroke—amounting to roughly 8 additional cases per 10,000 women annually for each condition. For women initiating therapy between ages 50 and 59, all-cause mortality does not increase. It should never be prescribed to prevent heart disease or dementia.

Requires a consultation at a gynecology or menopause specialty clinic. The clinician evaluates medical history and contraindications before prescribing appropriate regimens. Regular follow-up checkups are mandatory during therapy. The primary hurdle is overcoming unfounded fears that "all hormones immediately cause cancer," while avoiding over-the-counter anti-aging marketing claims.

A Cochrane systematic review of 24 randomized controlled trials involving 3,329 women compared oral hormone therapy with placebo: women receiving hormone therapy experienced an approximate 75% reduction in weekly hot flushes compared to placebo (95% CI 64.3–82.3), alongside a significant reduction in symptom severity (OR 0.13, 95% CI 0.07–0.23). Women in placebo arms also experienced a 57.7% reduction in symptoms, demonstrating why controlled comparisons are critical. Adverse event risk profiles were established by the landmark U.S. Women's Health Initiative (WHI) randomized trial involving 16,608 postmenopausal women aged 50–79 with an intact uterus receiving combined estrogen plus progestin (mean follow-up 5.2 years): coronary heart disease increased by 29% (HR 1.29, 95% CI 1.02–1.63), invasive breast cancer increased by 26% (HR 1.26, 95% CI 1.00–1.59), stroke increased by 41% (HR 1.41, 95% CI 1.07–1.85), and pulmonary embolism increased 2.13-fold (HR 2.13, 95% CI 1.39–3.25). In absolute numbers, this corresponds to approximately 7 additional cases of coronary disease, 8 additional strokes, 8 additional pulmonary embolisms, and 8 additional invasive breast cancers per 10,000 women per year, alongside 6 fewer colorectal cancers and 5 fewer hip fractures. Conversely, for women with prior hysterectomy receiving estrogen alone, cumulative 13-year follow-up showed a 21% reduction in breast cancer incidence (HR 0.79, 95% CI 0.65–0.97). Across 18 years of cumulative follow-up for both trials combined, all-cause mortality did not differ between hormone therapy and placebo (HR 0.99, 95% CI 0.94–1.03). In age-stratified analyses, women initiating therapy between ages 50 and 59 experienced a 31% reduction in all-cause mortality during the intervention phase (HR 0.69, 95% CI 0.51–0.94), whereas older cohorts showed no mortality benefit (ages 60–69: HR 1.04; ages 70–79: HR 1.13); at 18-year post-intervention follow-up, the mortality difference in the 50–59 group was no longer statistically significant (HR 0.89, 95% CI 0.79–1.01). A 2017 Cochrane review focusing on women aged 50–59 noted venous thromboembolism as the only significantly elevated risk with combined therapy, with an absolute incidence under 1 in 500. In women aged 65 and older on combined therapy, dementia diagnoses rose from 9 to 11–30 cases per 1,000 women over 4 years. The U.S. Preventive Services Task Force (USPSTF) 2022 recommendation explicitly advises against using hormone therapy for the primary prevention of chronic conditions in postmenopausal persons (Grade D recommendation), finding no net clinical benefit.

Controversy: WHI participants averaged 63 years of age and received standard oral conjugated equine estrogens plus medroxyprogesterone acetate; modern clinical practice typically initiates low-dose personalized regimens in women in their early 50s at the onset of severe perimenopausal symptoms. The mortality reduction observed in the 50–59 age bracket was a subgroup finding that attenuated over 18 years, meaning hormone therapy cannot be characterized as a life-extending longevity intervention. Contraindications generally include previous breast cancer, active or prior thromboembolism, high cardiovascular risk, and severe obesity, requiring individual clinical assessment. Women with an intact uterus must pair estrogen with a progestin to prevent endometrial hyperplasia and cancer; estrogen alone is reserved for individuals with prior hysterectomy. While hormone therapy reduces osteoporotic fractures, it is reserved for symptom control or cases where first-line osteoporosis drugs cannot be tolerated (see Chapter 1, Rules 39 and 40). Benefit magnitude is rated High based on the 75% reduction in severe vasomotor symptoms. Primary beneficiaries are yourself, your mother, or your partner.

MacLennan AH, Broadbent JL, Lester S, Moore V (2004). Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews, (4), CD002978. https://doi.org/10.1002/14651858.CD002978.pub2；Writing Group for the Women's Health Initiative Investigators, Rossouw JE, Anderson GL, Prentice RL, 等 (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321-333. https://doi.org/10.1001/jama.288.3.321；Manson JE, Chlebowski RT, Stefanick ML, 等 (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 310(13), 1353-1368. https://doi.org/10.1001/jama.2013.278040；Manson JE, Aragaki AK, Rossouw JE, 等 (2017). Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA, 318(10), 927-938. https://doi.org/10.1001/jama.2017.11217；Marjoribanks J, Farquhar C, Roberts H, 等 (2017). Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews, (1), CD004143. https://doi.org/10.1002/14651858.CD004143.pub5；US Preventive Services Task Force, Mangione CM, Barry MJ, 等 (2022). Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: US Preventive Services Task Force recommendation statement. JAMA, 328(17), 1740-1746. https://doi.org/10.1001/jama.2022.18625